NEWPORT BEACH, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Mammogen, a female-led predictive health company developing RNA-powered molecular diagnostics for women’s health, today appointed Elise Berman, M.D., as Chief Medical Officer. Dr. Berman brings more than two decades of leadership across breast imaging, medical affairs, and clinical development. She joins Mammogen as the company advances genTRU-breast™ through clinical validation and toward commercialization.

Mammogen has announced the successful completion of a Series A financing round of up to $30 million, marking a significant milestone in the company's mission to transform breast cancer detection through innovative blood-based diagnostics.

Renowned global builder of boards and executive teams aligns with leading women's health innovator, signaling next phase of commercial growth

Did you know that mammograms have remained virtually unchanged since their invention in 1913? It's no wonder they feel archaic!

Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm